Graham Robinson, P.C.

Partner Mergers & Acquisitions Private Equity

Boston +1 617 385 7737

Graham Robinson, P.C.

Practices

Overview

“Graham is able to distill complex issues so that they are simple and actionable. His understanding of the market is unparalleled. - Chambers USA (Client Quote)

Graham Robinson is an M&A partner in the Boston office of Kirkland & Ellis LLP. Graham’s practice focuses on transactions involving the acquisitions of public companies, specifically within the biopharmaceutical industry. He is ranked first by deal value and number of deals among U.S. attorneys for public biotechnology M&A transactions since January 2016, according to Deal Point Data. Graham also has extensive experience within the shareholder activism space. He has helped companies prepare for and respond to unsolicited acquisition proposals, as well as dealing with activist investors. He provides counsel to boards of directors and special committees on corporate governance matters and internal investigations.

Graham has been recognized in the most recent rankings of Chambers Global, Chambers USA, The Legal 500 and The Best Lawyers in America, which named him its 2023 Boston Mergers & Acquisitions Law Lawyer of the Year. He was also named a 2024 Law360 MVP in the Life Sciences category. He has also been named one of MergerLinks’ Top Healthcare Lawyers in North America and Top Advisor Lawyers in North America.

Since joining Kirkland, Graham has been involved in the following matters:

  • Anne Wojcicki’s not-for-profit TTAM Research Institute in its pending acquisition of 23andMe, a human genetics and biotechnology company
  • Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company, in its pending $795 million sale to Supernus Pharmaceuticals (Nasdaq: SUPN)

Prior to joining Kirkland, Graham was involved in transactions for the following companies, among others:

Biopharmaceutical M&A

  • Represented a principal or financial advisor in the sales of the following companies:
    • Acceleron Pharma, Achillion Pharmaceuticals, Aerie Pharmaceuticals, Akcea Therapeutics, Alder Biopharmaceuticals, Alpine Immune Sciences, Ambrx, Antares Pharma, Arena Pharmaceuticals, ArQule, Array BioPharma, BELLUS Health, Biohaven Pharmaceuticals, Cerevel Therapeutics, CerSci Therapeutics, Chimerix, CinCor Pharma, Clementia Pharmaceuticals, Constellation Pharmaceuticals, CTI Biopharma, CymaBay Therapeutics, Dicerna Pharmaceuticals, Dimension Therapeutics, Evergreen Theragnostics, EyeBio, Five Prime Therapeutics, Forty Seven, GW Pharmaceuticals, Inhibrx, Intercept Pharmaceuticals, Intra-Cellular Therapies, Iveric Bio, Juno Therapeutics, Kite Pharma, Mirati Therapeutics, Momenta Pharmaceuticals, MorphoSys, Nightstar Therapeutics, Nimbus Apollo, NPS Pharmaceuticals, Pandion Therapeutics, POINT Biopharma, Portola Pharmaceuticals, Prometheus Biosciences, Seagen, Sierra Oncology, SpringWorks Therapeutics, Stemline Therapeutics, Tobira Therapeutics, Translate Bio and Turning Point Therapeutics

Technology & Other Industries

  • Represented a principal or financial advisor in the sales of the following companies:
    • Bottomline Technologies, Boston Dynamics, Carbonite, Logility, Qlik Technologies, Walgreens Boots Alliance and WeWork

Special Committees

  • In addition, Graham has substantial experience representing special committees in connection with company sales, including for the following companies:
    • Aspen Technologies, EngageSmart, Legg Mason and R1 RCM

Law ClerkHonorable J. Curtis JoynerUnited States District Court for the Eastern District of Pennsylvania

Partner, Skadden, Arps, Slate, Meagher & Flom LLP

More

Recognition

Recognized by Chambers USA for Corporate/M&A in Massachusetts

Recognized by Chambers Global for Corporate/M&A (International & Cross-Border) USA

Named one of MergerLinks’ Top Healthcare Lawyers in North America and Top Advisor Lawyers in North America

Recognized by The Best Lawyers in America as the Boston Mergers & Acquisitions Law Lawyer of the Year, 2023

Recognized by Lawdragon as one of the 500 Leading Lawyers in America and one of the 500 Leading Dealmakers in America

Recognized by Law360 as an MVP in Life Sciences

Recognized by The Legal 500 United States for M&A: Large Deals ($1bn+) and Healthcare - Life Sciences

Listed on The Legal 500 United States’ M&A Private Practice Powerlist in 2023

Recognized by LMG Life Sciences as Attorney of the Year in 2021

Recognized as a Client Choice Award Winner in 2018

Named by The M&A Advisor as one of the Top 40 M&A Professionals Under 40

Named by the Boston Business Journal as one of its 40 Under 40 Business and Civic Leaders in the City of Boston

Memberships & Affiliations

Overseer, Boston Symphony Orchestra

Former Member of the Board of Fellows, Harvard Medical School

Former Member of the Board of Directors, Massachusetts Chapter of the March of Dimes

Credentials

Admissions & Qualifications

  • Massachusetts
  • New York

Education

  • Harvard Law SchoolJ.D.1999
  • University of PennsylvaniaB.A.1996